Discontinue immediately if paradoxical bronchospasm w/ immediate increase in wheezing after dosing occurs. Not to be used in patients w/ hypersensitivity; invasive fungal infections except in necessary cases. Not for relief of acute symptoms requiring fast- & short-acting bronchodilator (eg, salbutamol). Not to be stopped abruptly in patients w/ asthma due to risk of exacerbation. Sudden & progressive deterioration in asthma control. Symptomatic decompensation in patient w/ COPD cessation of therapy. Possible development of pneumonia in patients w/ COPD; systemic effects eg, Cushing's syndrome, cushingoid features, adrenal suppression, growth retardation in adolescents & childn, decreased bone mineral density, cataract, glaucoma; impaired adrenal response. CV effects eg, increased systolic BP & heart rate; transient decrease in serum K at higher dose; tremor, subjective palpitations, headache. Patients w/ gastroenteritis, current or history of DM, active or quiescent pulmonary TB, viral infections; thyrotoxicosis; pre-existing CV disease; predisposition to low serum K levels. Gradually w/draw systemic therapy following initiation of inhaled fluticasone propionate. Regularly monitor height of childn receiving prolonged treatment; adrenocortical function. Avoid concomitant use w/ ritonavir. Concomitant use w/ CYP3A4 inhibitors eg, ketoconazole. Pregnancy & lactation. Childn <4 yr w/ asthma (reversible obstructive airways disease).
Sign Out
